Medivir
  • About us
  • Our projects
  • About cancer
  • Investors
  • News and media
  • Connect
  • Svenska
About us
  • Medivir in brief
    • Business concept & Strategy
      • Leadership
        • Management team
        • Board of Directors
      • History
        • EFPIA Disclosure
          Our projects
          • Proprietary
            • Fostroxacitabine bralpamide (fostrox)
          • Projects for licensing
            • Remetinostat
            • MIV-711
          • Partnerships
            • Birinapant/IGM-9427
            • Xerclear®
            • USP-7
            • MBLI/MET-X
          • Publications
            About cancer
            • About cancer
              Investors
              • Stock information
                • Reports
                  • Financial reports 2025
                  • Financial reports 2024
                  • Financial reports 2023
                  • Financial reports 2022
                  • Financial reports 2021
                  • Financial reports 2020
                  • Financial reports 2019
                  • Financial reports 2018
                  • Financial reports 2017
                  • Financial reports 2016
                • Presentations
                  • Presentations 2025
                  • Presentations 2024
                  • Presentations 2023
                  • Presentations 2022
                  • Presentations 2021
                • Press releases
                  • Subscribe
                • Calendar
                  • Redeye Investor Forum Stockholm
                  • Interim Report, January - June 2025 (webcast)
                  • Interim Report, January - September 2025 (webcast)
                • Corporate Governance
                  • General Meetings
                    • 2025
                    • 2024
                    • 2023
                    • 2022
                    • 2021
                    • 2020
                  • Rights issue 2023
                    News and media
                      Connect
                      • Connect with Medivir
                        • Partner with Medivir
                          Search
                          Subscribe to press releases
                          Address

                          Medivir AB
                          Box 1086
                          SE-141 22 Huddinge
                          Visit: Lunastigen 5, 2nd floor

                          Phone +46 (0)8 5468 31 00 Email info@medivir.com
                          Our privacy policy

                          Read more

                           

                          Jens Lindberg

                          Chief Executive Officer

                          jens.lindberg@medivir.com
                           

                          Magnus Christensen

                          Chief Financial Officer

                          magnus.christensen@medivir.com